Polpharma Biologics has officially launched Ranivisio PFS, a ranibizumab biosimilar in a pre-filled syringe format, now available to patients and healthcare providers in France. This marks the first time a Lucentis biosimilar has been offered in a pre-filled syringe presentation in Europe, making it a significant step forward in the accessibility and convenience of ophthalmic biologics. Designed for the treatment of neovascular (wet) age-related macular degeneration, diabetic macular edema, and retinal vein occlusion, the product aims to simplify administration and ensure accurate dosing for patients and clinicians alike.
Health Technology Insights: Dermatology of Miami Adds Dr. George Glinos to Team
Ranivisio PFS was developed and licensed by Bioeq AG, a joint venture between Polpharma Biologics Group BV and Formycon AG. Commercial rights in France are held by Teva, which distributes the product under an exclusive agreement with Bioeq. The active substance used in the pre-filled syringe is produced by Polpharma Biologics S.A., operating under the Rezon Bio brand. The company’s facilities in Poland are responsible for the commercial-scale production of the drug substance, emphasizing high standards of consistency and reliability.
Health Technology Insights: Cohere Health Launches AI Prior Authorization Tool
Anjan Selz, CEO of Polpharma Biologics, highlighted the importance of this launch as part of the company’s broader commitment to increasing access to biologic therapies. He noted that offering the first Lucentis biosimilar in a ready-to-use syringe format represents a new benchmark in ophthalmic care. According to Selz, the goal is to provide high-quality, innovative treatment options that not only meet medical needs but also improve convenience for both patients and healthcare professionals.
Health Technology Insights: LGC Group Opens New UK Labs to Boost Measurement Science
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source- businesswire
